[New drug approval: Adjuvant Pembrolizumab in clear-cell renal-cell carcinoma at high risk for recurrence after nephrectomy].

Maxime Brunet, Gabriel G Malouf

Bulletin du cancer(2022)

引用 0|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要